Randomized comparison of ciclesonide 160 and 640 μg/day in severe asthma

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 3, 2008, Pages 489-498

  Bateman, E D ^a   Cheung, D ^b   Lapa e Silva, J ^c   Gohring U M ^d   Schafer M ^d   Engelstatter R ^d  

^a Faculty of Health Sciences   (South Africa)

^b Vlietland Ziekenhuis   (Netherlands)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d ALTANA PHARMA AG   (Germany)

Author keywords

Asthma; Ciclesonide; Cortisol; Exacerbations; Fluticasone propionate; Forced expiratory volume in 1 s

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CICLESONIDE; CREATININE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HYDROCORTISONE; SALBUTAMOL; XANTHINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; THRUSH;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; CANDIDIASIS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PREGNENEDIONES; QUALITY OF LIFE; VITAL CAPACITY;

EID: 43049093725     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.11.002     Document Type: Article

References (32)

1. GINA Global Initiative for Asthma. Global strategy for asthma management and prevention, 2005.
2. NIH National Institutes of Health National Heart Lung and Blood Institute. National asthma education and prevention program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics. J Allergy Clin Immunol 110 (2002) S129-S141
3. Boulet L. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 113 (1998) 587-592
4. Halterman J.S., Aligne C.A., Auinger P., McBride J.T., and Szilagyi P.G. Inadequate therapy for asthma among children in the United States. Pediatrics 105 1, Part 3 (2000) 272-276
5. Kips J. Managing a variable disease. Pulm Pharmacol Ther 15 6 (2002) 485-490
6. Powell H., and Gibson P.G. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 178 5 (2003) 223-225
7. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170 8 (2004) 836-844
8. Foresi A., Morelli M.C., and Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 117 2 (2000) 440-446
9. Simons F.E. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol 102 5 (1998) S77-S84
10. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159 (1999) 941-955
11. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 61 5 (2006) 518-526
12. Newman S., Salmon A., Nave R., and Drollmann A. High lung deposition of (99m)Tc labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100 3 (2006) 375-384
13. Dietzel K., Engelstatter R., and Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res 31 (2001) 91-93
14. Nave R., Bethke T., Marle Sv., and Zech K. Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43 7 (2004) 479-486
15. Rohatagi S., Arya V., Zech K., Nave R., Hochhaus G., Jensen B.K., et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43 4 (2003) 365-378
16. Chapman K.R., Patel P., D'Urzo A.D., Alexander M., Mehra S., Oedekoven C., et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 60 3 (2005) 330-337
17. Langdon C.G., Adler M., Mehra S., Alexander M., and Drollmann A. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99 10 (2005) 1275-1285
18. Lipworth B.J., Kaliner M.A., LaForce C.F., Baker J.W., Kaiser H.B., Amin D., et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94 4 (2005) 465-472
19. Derom E., Van De Velde V., Marissens S., Engelstatter R., Vincken W., and Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5' monophosphate in asthmatic patients. Pulm Pharmacol Ther 18 5 (2005) 328-336
20. Postma D.S., Sevette C., Martinat Y., Schlosser N., Aumann J., and Kafe H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17 6 (2001) 1083-1088
21. O'Connor B., Sips P., Engelstatter R., Steinijans V., and Wurst W. Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial. Am J Respir Crit Care Med 165 8 (2002) A767
22. Busse W., Kaliner M., Bernstein D., Nayak A., Kundu S., Williams J., et al. The novel inhaled corticosteroid ciclesonide is efficacious and has a favorable safety profile in adults and adolescents with severe persistent asthma. J Allergy Clin Immunol 115 2 (2005) [Abstract 846]
23. ATS American Thoracic Society. Standardization of spirometry 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
24. Juniper E., Buist A., Cox F., Ferrie P., and King D. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 115 (1999) 1265-1270
25. GINA. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2003.
26. Masoli M., Weatherall M., Holt S., and Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 59 1 (2004) 16-20
27. Bateman E., Karpel J., Casale T., Wenzel S., and Banerji D. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 129 5 (2006) 1176-1187
28. Bernstein D.I., Berkowitz R.B., Chervinsky P., Dvorin D.J., Finn A.F., Gross G.N., et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 93 9 (1999) 603-612
29. Adams N.P., Bestall J.C., Jones P.W., Lasserson T.J., Griffiths B., and Cates C. Inhaled fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 1 (2005) CD003534
30. Fiel S.B., and Vincken W. Systemic corticosteroid therapy for acute asthma exacerbations. J Asthma 43 5 (2006) 321-331
31. Andersson F., Borg S., and Stahl E. The impact of exacerbations on the asthmatic patient's preference scores. J Asthma 40 6 (2003) 615-623
32. Engelstaetter R., Escher A., and Haefner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 26 Suppl. 49 (2005) 255s